Evermay Wealth Management LLC Has $296,000 Holdings in Pfizer Inc. $PFE

Evermay Wealth Management LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 13.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,211 shares of the biopharmaceutical company’s stock after selling 1,884 shares during the period. Evermay Wealth Management LLC’s holdings in Pfizer were worth $296,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new stake in Pfizer during the 1st quarter worth approximately $27,000. North Capital Inc. bought a new stake in shares of Pfizer during the first quarter worth $28,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the first quarter worth $28,000. Harbor Asset Planning Inc. bought a new stake in Pfizer in the 2nd quarter valued at $29,000. Finally, Horizon Financial Services LLC acquired a new position in Pfizer in the 1st quarter worth $35,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 1.2%

NYSE:PFE opened at $24.52 on Monday. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $29.36. The firm has a market capitalization of $139.38 billion, a price-to-earnings ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock’s 50 day moving average price is $24.89 and its two-hundred day moving average price is $24.11.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period last year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PFE shares. Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Morgan Stanley cut their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.